SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?


To: Daveyk who wrote (753)3/10/2000 5:45:00 PM
From: Bosco  Read Replies (3) | Respond to of 1298
 
Hi David - being cautious is not a bad approach. So, I think you did the prudent thing. If I were you, I would want to protect my profit too~ It is hard to say if this is the bottom, especially the biotech sector is even more volatile than the net stocks, which begs a question of my sanity <G>: for the longest time I ve resisted getting into netmania. Then, all of the sudden 2 weeks ago, I moved 25% of my portfolio money [was deep in cash] into the drug/biotech/med device sector, with varying success. My smaller CHIR position and my bigger CEGE position cancel each other out [thanks goodness for the recent change of fortune in CHIR.] All in all, I am close to even [maybe a little red]

With the upcoming conference, I am hopeful that the informed will see the differences between a good biotech and a has been.

For giggle, I checked ABGX [I don't own it directly] and I see it is still ok. With the 1/4 billion dollars in the bank and ~2.5MM shares of ABGX, I am paying 5 bucks for 200 patents and 350 apps patents. While some of them may be secondary patents, I think CEGE has a good bunch of patents who can provide steady steam of loyalty for a long time to come.

The only downside is that we may have a AMZN symdrome. You know, people prefer to buy companies who are bleeding like crazy and who do not have a real killer apps.

Therefore, I am going to have faith in this one and ride her a bit longer.

best, Bosco